Tissue Regenix Group plc TSSNF OTC

Tissue Regenix Group plc (TSSNF) generated $-1.64M in operating cash flow for fiscal year 2024. After capital expenditures of $4.07M, free cash flow was $-5.7M.

Free cash flow margin was -19.9% of revenue. Cash conversion ratio was 4.17x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (43/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (10/100) — Cash conversion ratio was 4.17x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 41/100 with 1/7 criteria passed.